D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD

Xueliang Fan\textsuperscript{a} and Ellen J. Hess\textsuperscript{a, b, *}

\textsuperscript{a}Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
\textsuperscript{b}Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

Received 18 September 2006; revised 5 December 2006; accepted 20 December 2006
Available online 29 December 2006

The mechanisms underlying the effects of psychostimulants in attention deficit hyperactivity disorder (ADHD) are not well understood, but indirect evidence implicates D2 dopamine receptors. Here we dissect the components of dopaminergic neurotransmission in the hyperactive mouse mutant \textit{coloboma} to identify pre- and postsynaptic elements essential for the effects of amphetamine in these mice. Amphetamine treatment reduced locomotor activity in \textit{coloboma} mice, but induced a robust increase in dopamine overflow suggesting that abnormal regulation of dopamine efflux does not account for the behavioral effect. However, the D2-like dopamine receptor antagonists haloperidol and raclopride, but not the D1-like dopamine receptor antagonist SCH23390, blocked the amphetamine-induced reduction in locomotor activity in \textit{coloboma} mice, providing direct evidence that D2-like dopamine receptors mediate the effect of amphetamine in these mice. With the precedent established that it is possible to directly antagonize this response, this strategy should prove useful for identifying novel therapeutics in ADHD.

© 2006 Elsevier Inc. All rights reserved.

Keywords: Hyperactivity; \textit{Coloboma}; Dopamine receptor; Amphetamine; ADHD; Microdialysis; SNAP-25; Raclopride; Adenylate cyclase; Catalepsy; Haloperidol; SCH23390

Introduction

Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, impulsivity and hyperactivity. A familiar feature of ADHD is the response to psychostimulants such as methylphenidate (Ritalin) and \textit{d}-amphetamine (Adderall). Both compounds are indirect agonists that increase extracellular monoamine concentrations (Ferris et al., 1972; Heikkila et al., 1975). In ADHD patients, low doses of stimulants produce beneficial behavioral effects by reducing excess motor activity and enhancing concentration. Although the efficacy of psychostimulants in ADHD was recognized nearly 70 years ago (Bradley, 1937), the biological mechanisms are not understood.

Many theories, including several that focus on dopaminergic transmission, have emerged to explain the effects of psychostimulants. The rate dependency hypothesis suggests that the effect of psychostimulants in hyperactive children is a phenomenon driven by behavioral state (Glick and Milloy, 1973; Sahakian and Robbins, 1977). The locomotor response to psychostimulants is an inverted U-shaped function: low doses increase locomotor activity and high doses induce focused behaviors (stereotypy) that compete with and consequently reduce locomotor activity. Drug-naive ADHD patients are at the highest point on this inverted U-shaped curve. Accordingly, the psychostimulant-induced reduction in motor activity is ascribed to an increase in stereotyped behavior. Others propose that low doses of direct-acting dopamine agonists preferentially interact with presynaptic receptors to inhibit dopamine release and therefore reduce locomotor activity (Skirboll et al., 1979). By extension, it is proposed that low doses of the indirect agonists methylphenidate and amphetamine reduce locomotor activity in ADHD patients through a similar mechanism of action. Others suggest that psychostimulant therapy compensates for insufficient dopamine transmission in the frontal cortex while reducing nigrostriatal overactivity (Castellanos, 1997). Despite these and other well-developed hypotheses, there is little empirical evidence to explain the therapeutic mechanism of psychostimulants in ADHD.

Animal models of ADHD provide an opportunity to explore pathogenic and therapeutic mechanisms. The \textit{coloboma} mouse mutant is one such model. These mice exhibit hyperactivity, inattention and delayed developmental milestones (Hess et al., 1992; Heyser et al., 1995; Bruno et al., 2007) plus abnormal monoaminergic regulation (Raber et al., 1997; Jones and Hess, 2003). These defects are attributable, at least in part, to a reduction in the expression of SNAP-25 (Hess et al., 1996), a protein...
essential for neurotransmitter exocytosis (Söllner et al., 1993). The phenotype results from a hemizygous deletion mutation that includes the Snap25 gene (Hess et al., 1992); several independent research groups have determined that there is also a genetic association between the SNAP25 gene and ADHD in humans (Barr et al., 2000; Brophy et al., 2002; Mill et al., 2002; Kustanovich et al., 2003; Brookes et al., 2006). Indeed, a recent meta-analysis also supports this association (Faraone et al., 2005). Similar to its effects on ADHD patients, amphetamine reduces locomotor activity in coloboma mice (Hess et al., 1996). Here we dissect the components of dopaminergic neurotransmission in coloboma mice to identify elements essential for the effect of amphetamine.

Materials and methods

Mice

Coloboma (Cm/+i) mice were bred and housed in group cages at the Johns Hopkins University vivarium. In all experiments, coloboma mice and wild type control littermates (4–9 months of age) were age- and sex-matched, although there is no significant difference in the locomotor activity between males and females. Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the National Institutes of Health.

Drugs and receptor nomenclature

Drugs were purchased from Sigma (St. Louis, MO) and injected intraperitoneally in a volume of 10 ml/kg; apomorphine was injected subcutaneously. Haloperidol and spiperone interact with D2, D3 and D4 dopamine receptors; both are butyrophenone compounds. Raclopride is a D2/D3 dopamine receptor antagonist but is a substituted benzamide. Quinpirole is a D2/D3 dopamine receptor agonist. SCH23390 is selective for D1-like dopamine receptors (D1 and D5 dopamine receptors). Apomorphine is a nonselective dopamine agonist. Although there are at least 5 different molecularly defined dopamine receptors, pharmacological agents generally discriminate only between the broad classes of D1-like and D2-like dopamine receptors.

Locomotor activity

Control and coloboma mice were tested in 16 automated photocell activity cages (29×50 cm) equipped with 12 infrared beams arranged in a 4×8 grid (San Diego Instruments; San Diego, CA). Computer-recorded beam breaks were accumulated every 10 min for the duration of the test period with changes in beam status assessed 18 times/s. Control and coloboma littersmates were tested in parallel on the same test days and were habituated to the status assessed 18 times/s. Control and coloboma mice had access to food and water ad libitum for at least 4 h prior to drug injection. Mice had access to food and water ad libitum during the entire test. Drug was injected 1 h after the start of the dark cycle and locomotor activity was recorded for 2 h after drug injection.

Within each experiment, mice were tested in a repeated measures design. For all behavioral tests, the order of drug doses and vehicle was pseudorandom with each mouse receiving every dose only once within an experiment. Mice were given a 4-day drug holiday between challenges to avoid supersensitivity. For amphetamine tests, mice were challenged with 4 mg/kg amphetamine after the entire experiment was complete to ensure that supersensitivity had not developed; in all groups, there was no evidence for supersensitivity as assessed by both locomotor activity and stereotypy scores. The dose–responses were analyzed using repeated measures ANOVAs followed by post hoc paired t tests where appropriate.

Although there is no clear formula for converting human doses to mouse, 4 mg/kg amphetamine was selected based on the pharmacokinetic species differences and dose range in humans. The typical therapeutic dose range for amphetamine in humans is 0.2–0.5 mg/kg and drug half-life is ~6–8 h (Brown et al., 1979; Greenhill et al., 2003). In contrast, the half-life of amphetamine in mice is ~20–50 min (Miller et al., 1971; Fuller et al., 1972; Riffee et al., 1978), as much as 20-fold faster clearance than in humans.

Stereotypy

During the 2 h locomotor activity tests, mice were rated for stereotypy under red light illumination every 10 min for 30 s. A 0–5 behavioral scale was used to score stereotypy: 0=sleeping; 1=awake, inactive; 2=active or exploring; 3=hyperactive; 4=hyperactive with bursts of stereotypic behavior; and 5=continuous persistent stereotypy. The first stereotypy rating was made 10 min after drug injection.

Microdialysis

Microdialysis was performed in alert, freely moving mice. Concentric microdialysis probes were constructed as previously described (Page et al., 2003). Recovery rates averaged 10±0.5%.

Mice were anesthetized with tribromoethanol (Avertin), positioned in a stereotoxic apparatus (Stoelting, Wood Dale, IL) and a microdialysis probe was implanted in the striatum (+0.6 AP, +1.7 ML, +4.5 DV). After surgery, the probe was perfused continuously with artificial cerebrospinal fluid (aCSF: 147 mM NaCl, 3.5 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 1 mM NaH2PO4, 25 mM NaHCO3, pH 7.0–7.4) at a flow rate of 1.5 μl/min. For conventional microdialysis, samples were collected 14–16 h after surgery at 20 min intervals. Four consecutive samples were collected as baseline. Then 10 samples were collected after injection of amphetamine. For no net flux microdialysis, the probe was perfused with aCSF containing 250 μM ascorbic acid at a flow rate of 0.3 μl/min overnight. Flow rate was then increased to 0.6 μl/ min and the probe perfused with the aforementioned perfusate plus different concentrations of dopamine (0, 2, 10 or 20 nM; Cini in pseudorandom order. Following a 25-min equilibration period, 3 samples were collected (Cout). The perfusate dopamine concentration was then switched and the process repeated until all dopamine concentrations were tested. After completion of the experiment, brains were removed and probe location was confirmed; only animals with probes in the striatum were included.

Samples were analyzed by HPLC (MD-150 column, 150 mm length; 3 mm I.D.; ESA, Chelmsford, MA) equipped with a S104B coulometric microdialysis cell. The mobile phase consisted of 1.7 mM 1-octanesulfonic acid sodium salt, 25 μM EDTA, 75 mM NaH2PO4 and 8% acetonitrile (pH 2.9) at a flow rate of 0.6 ml/min. Neuropeptides were identified by matching retention time to that of known standards. For conventional microdialysis, values were expressed as ng/ml after adjustment for recovery rate of the microdialysis probe. For no net flux microdialysis, data were subjected to a linear regression analysis plotting the gain or loss of dopamine from the perfusate (Cin − Cout) versus Cout. The x-intercept...
(C in−C out=0) provides an unbiased estimate of extracellular dopamine concentration; the slope represents the extraction fraction, which is an indirect measure of dopamine uptake (Smith and Justice, 1994; Shippenberg et al., 1999). Data were analyzed using two-factor ANOVA or Student’s t test, where appropriate.

**Catalepsy**

Catalepsy was tested by gently placing both front paws of a mouse on a horizontal bar (0.5 cm diameter) 4 cm above the cage (28×17×13 cm) floor. Time was measured from the placement of the forepaws until both forepaws were removed from the bar or the mouse moved both forepaws to the left or right on the bar. Cutoff time was 180 s for each trial. Each mouse was tested in 3 consecutive trials per session unless one of the trials reached the cutoff time; in this case, no further trials were run. The average of 3 trials or 180 s, if cutoff was achieved, was used to calculate catalepsy. Catalepsy was tested in 20 min intervals for 2 h starting 10 min after injection and analyzed using repeated measures ANOVAs.

**Adenylate cyclase activity**

Striata from individual mice were homogenized and centrifuged in buffer containing 10 mM imidazole (pH 7.4), 2 mM EDTA and 10% sucrose. The pellet was resuspended in buffer containing 10 mM imidazole (pH 7.4), 2 mM EDTA, 0.5 mM DTT and 10% sucrose. The reaction was performed (±quinpirole) in a 100 μl volume containing 80 mM Tris–HCl (pH 7.4), 150 mM NaCl, 4 mM MgCl2, 2 mM EDTA, 0.5 mM IBMX, 2 mM ATP, 20 mM phosphocreatine, 5 U of creatine phosphokinase, 1 mg BSA, 100 μM GTP and 0.1 μM forskolin at 37 °C for 7 min. About 15 μg membrane protein was added to each tube to start the reaction with triplicates for all conditions. The reaction was terminated by boiling the mixture for 3 min. After centrifuging the reaction mixture at 20,000×g for 20 min, cAMP accumulation was determined by radioimmunoassay (Amersham Biosciences, Piscataway, NJ). Protein concentration was determined using a Bio-Rad protein assay (Bio-Rad, Hercules, CA) and adenylate cyclase activity was expressed as pmol cAMP/mg protein/min. Data were analyzed using two-factor ANOVA with repeated measures.

**Results**

**D2-like dopamine receptor antagonist blocks the amphetamine-induced reduction in locomotor activity**

Consistent with previous results (Hess et al., 1996), 4 mg/kg amphetamine significantly reduced the locomotor hyperactivity exhibited by *coloboma* mice (*p<0.05; Fig. 1A). Stereotypic behavior was not observed at this dose of amphetamine (data not shown), suggesting that the reduction in locomotor activity in *coloboma* mice was not attributable to an increase in competing focused repetitive behaviors. To determine if the response to amphetamine is dependent on a specific dopamine receptor subtype, mice were challenged with amphetamine in the presence of subtype-selective antagonists. The D2-like dopamine receptor antagonist haloperidol blocked the amphetamine-induced reduction in locomotor activity in *coloboma* mice compared to amphetamine alone (Fig. 1A). In *coloboma* mice, 0.05 mg/kg haloperidol caused a significant 44% attenuation in amphetamine-mediated locomotor activity (*p<0.05*). By itself, this low dose of haloperidol did not affect locomotor activity. Even 0.3 mg/kg haloperidol, which caused a marked reduction in baseline locomotor activity (*p<0.05*), blocked amphetamine-attenuated locomotor activity in *coloboma* mice (*p=0.05*).

In contrast to *coloboma* mice, amphetamine induced a two-fold increase in locomotor activity in control mice (*p<0.001*). Surprisingly, 0.05 mg/kg haloperidol also produced a small, but significant increase (16%) in amphetamine-stimulated motor activity (*p<0.05*). By itself, this low dose of haloperidol did not affect locomotor activity. Even 0.3 mg/kg haloperidol, which caused a marked reduction in baseline locomotor activity (*p<0.05*), blocked amphetamine-attenuated locomotor activity in *coloboma* mice (*p=0.05*).
activity in wild type mice ($p<0.05$; Fig. 1B). However, amphetamine-stimulated locomotor activity was significantly reduced with 0.3 mg/kg haloperidol ($p<0.001$). Treatment with haloperidol alone dose-dependently reduced locomotor activity in both control and coloboma mice, although there was a significant genotype×dose interaction effect ($p<0.05$) suggesting that there was a differential response to haloperidol between genotypes. Stereotypy was not observed with any drug treatment in either control or coloboma mice (data not shown).

To determine if the response to haloperidol, which is a butyrophenone compound, was selective for D2-like dopamine receptors or if the response was determined by the chemical and pharmacological profile of haloperidol per se, the specificity of the effect for D2-like dopamine receptors was tested using the substituted benzamide raclopride, a D2/D3 dopamine receptor antagonist. Similar to the effects of haloperidol, 0.3 mg/kg raclopride caused a significant 54% attenuation in amphetamine-mediated locomotor activity in coloboma mice ($p<0.05$; Fig. 2A).

By itself, raclopride at all doses significantly reduced control or raclopride (Fig. 4A). However, amphetamine-stimulated locomotor activity was significantly reduced with 0.3 mg/kg haloperidol ($p<0.001$). Treatment with haloperidol alone dose-dependently reduced locomotor activity in both control and coloboma mice, although there was a significant genotype×dose interaction effect ($p<0.05$) suggesting that there was a differential response to haloperidol between genotypes. Stereotypy was not observed with any drug treatment in either control or coloboma mice (data not shown).

In contrast to coloboma mice, raclopride causes a dose-dependent reduction in the amphetamine-induced increase in locomotor activity in control mice (Fig. 2B). Treatment with raclopride alone dose-dependently reduced locomotor activity in both control and coloboma mice.

To determine if D1-like dopamine receptors also mediate the amphetamine-induced reduction in locomotor activity observed in coloboma mice, SCH23390, a D1/D5 dopamine receptor antagonist, was used in a similar series of amphetamine challenge experiments (Fig. 3). SCH23390 dose-dependently decreased amphetamine-mediated locomotor activity in both control and coloboma mice ($p<0.0001$). The SCH23390-induced reduction in amphetamine-mediated locomotor activity occurred in parallel in control and coloboma mice whereby a significant reduction in amphetamine-mediated locomotor activity was observed with 0.2 mg/kg SCH23390 treatment in both genotypes ($p<0.005$). Administration of 0.2 mg/kg SCH23390 alone also significantly reduced basal locomotor activity in both genotypes ($p<0.01$), while 0.05 mg/kg SCH23390 alone significantly reduced locomotor activity in only coloboma mice ($p<0.05$). At lower doses (0.0125 mg/kg or 0.00625 mg/kg, not shown), SCH23390 had no effect on basal or amphetamine-mediated locomotor activity.

Amphetamine is a nonselective indirect agonist that increases the extracellular concentration of norepinephrine and serotonin, in addition to dopamine. Therefore, apomorphine, a direct-acting mixed D1/D2 dopamine receptor agonist, was tested in a similar series of experiments to determine if selective activation of only dopamine receptors was sufficient to reproduce the effect. Responses to apomorphine are biphasic. Low doses of apomorphine act selectively at dopamine autoreceptors to reduce locomotor activity; we have previously demonstrated that the apomorphine-mediated autoreceptor response is normal in coloboma mice (Jones et al., 2001a). At higher doses, which were used in this experiment, apomorphine increases locomotor activity in normal rodents through its actions at postsynaptic dopamine receptors. As expected, 1 mg/kg apomorphine increased locomotor activity in control mice. At the same dose, apomorphine reduced locomotor activity in coloboma mice ($p<0.05$), similar to the effects of amphetamine. Stereotypy was not observed in either control or coloboma mice (data not shown). Consistent with theamphetamine challenge experiments, 0.05 mg/kg haloperidol blocked the apomorphine-induced reduction in locomotor activity in coloboma mice ($p<0.05$), while 0.0125 mg/kg SCH23390 had little effect on the apomorphine-induced reduction in locomotor activity (Fig. 4A). Neither haloperidol nor SCH23390 treatment significantly affected the apomorphine-induced increase in control mouse activity (Fig. 4B), although there was a trend toward a reduction in activity for both drugs.
Amphetamine-induced dopamine efflux is increased in the striatum of coloboma mice

Because the locomotor hyperactivity in coloboma mice results, at least in part, from a deficiency in SNAP-25, it is likely that presynaptic abnormalities contribute to the hyperactivity and abnormal response to amphetamine. Therefore, striatal dopamine efflux was assessed in alert freely moving mice. Basal extracellular dopamine concentrations were assessed using the no net flux method of microdialysis, which provides an unbiased estimate of transmitter concentration. Despite the reduction in SNAP-25 expression, the basal extracellular concentration of dopamine in coloboma mice exceeded that of control mice by more than 80% (Fig. 5A; *p < 0.05). In contrast, the extraction fraction, which is an indirect measure of dopamine uptake (Smith and Justice, 1994), was comparable in control and coloboma mice (Fig. 5B), suggesting that the increase in the basal extracellular dopamine concentration in coloboma mice is attributable to abnormalities in transmitter release. Consistent with the no net flux method, conventional dialysis also demonstrated a significant increase (*p < 0.05) in basal extracellular dopamine concentration in coloboma mice (data not shown). This increase in baseline

Fig. 3. Effect of the D1/D5 dopamine receptor antagonist SCH23390 on amphetamine-mediated locomotor activity. Coloboma (A) and control mice (B) were treated with saline or 4 mg/kg amphetamine and challenged with SCH23390. Compared to vehicle treatment, amphetamine significantly increased locomotor activity in control mice (**p < 0.01, paired Student’s t test) but significantly reduced locomotor activity in coloboma mice (*p < 0.05, paired Student’s t test). Two-factor ANOVA with repeated measures revealed a significant effect of genotype (F(1,12) = 25.22, p < 0.001) and dose of SCH23390 (F(3,36) = 18.41, p < 0.0001) on amphetamine-mediated locomotor activity. 0.2 mg/kg SCH23390 resulted in a significant reduction in amphetamine-mediated behavior in both control and coloboma mice (##p < 0.01). Two-factor ANOVA with repeated measures for treatment with SCH23390 alone revealed significant main effects of genotype (F(1,12) = 10.09, p < 0.01) and dose (F(2,24) = 4.45, p < 0.05). Compared to vehicle treatment (paired Student’s t tests), 0.2 mg/kg SCH23390 significantly reduced locomotor activity in control and coloboma mice (***p < 0.001; ***p < 0.001); 0.05 mg/kg SCH23390 significantly reduced the locomotor activity of coloboma mice (*p < 0.05). Data represent total beam breaks in 1 h after drug administration and are expressed as mean ± SEM (n = 7/genotype/dose).

Amphetamine-induced dopamine efflux is increased in the striatum of coloboma mice

Because the locomotor hyperactivity in coloboma mice results, at least in part, from a deficiency in SNAP-25, it is likely that presynaptic abnormalities contribute to the hyperactivity and abnormal response to amphetamine. Therefore, striatal dopamine efflux was assessed in alert freely moving mice. Basal extracellular dopamine concentrations were assessed using the no net flux method of microdialysis, which provides an unbiased estimate of transmitter concentration. Despite the reduction in SNAP-25 expression, the basal extracellular concentration of dopamine in coloboma mice exceeded that of control mice by more than 80% (Fig. 5A; *p < 0.05). In contrast, the extraction fraction, which is an indirect measure of dopamine uptake (Smith and Justice, 1994), was comparable in control and coloboma mice (Fig. 5B), suggesting that the increase in the basal extracellular dopamine concentration in coloboma mice is attributable to abnormalities in transmitter release. Consistent with the no net flux method, conventional dialysis also demonstrated a significant increase (*p < 0.05) in basal extracellular dopamine concentration in coloboma mice (data not shown). This increase in baseline

Fig. 4. Effect of D1- and D2-like dopamine receptor antagonists on apomorphine-mediated locomotor activity. Coloboma (A) and control mice (B) were treated with saline or 1 mg/kg apomorphine and challenged with SCH23390 or haloperidol. Two-factor ANOVA with repeated measures revealed a significant genotype × treatment interaction effect (F(3,42) = 4.95, p < 0.005). Post hoc analyses demonstrated that, compared to vehicle treatment, apomorphine significantly reduced locomotor activity in coloboma mice (*p < 0.05, paired Student’s t test). A significant increase in apomorphine-mediated locomotor activity was observed after treatment with 0.05 mg/kg haloperidol in coloboma mice (##p < 0.01). Two-factor ANOVA with repeated measures for treatment with SCH23390 alone revealed significant main effects of genotype (F(1,12) = 10.09, p < 0.01) and dose (F(2,24) = 4.45, p < 0.05). Compared to vehicle treatment (paired Student’s t tests), 0.2 mg/kg SCH23390 significantly reduced locomotor activity in control and coloboma mice (***p < 0.001; ***p < 0.001); 0.05 mg/kg SCH23390 significantly reduced the locomotor activity of coloboma mice (*p < 0.05). Data represent total beam breaks in 1 h after drug administration and are expressed as mean ± SEM (n = 7/genotype/dose).
extracellular dopamine in coloboma mice was not obvious with previous in vitro assays (Raber et al., 1997, Jones and Hess, 2003), where steady-state basal extracellular concentrations are not readily assessed.

Conventional microdialysis was used to assess the effects of amphetamine on dopamine efflux. Although amphetamine reduced locomotor activity in coloboma mice, a dose-dependent increase in striatal dopamine efflux was observed in response to amphetamine challenge in both control and coloboma mice (Figs. 6A – C). Amphetamine-induced dopamine efflux was significantly higher in coloboma mice (p<0.001) even after normalizing for differences in basal extracellular dopamine concentrations (Fig. 6E).

To determine if the effect of haloperidol on amphetamine-inhibited locomotor activity in coloboma mice was mediated presynaptically, amphetamine-induced dopamine efflux was assessed in the presence of the lowest dose of haloperidol that blocked the amphetamine effect in coloboma mice. Haloperidol (0.05 mg/kg) had no effect on amphetamine-induced dopamine efflux in either control or coloboma mice (Figs. 6D and E) nor did this very low dose of haloperidol alone significantly affect basal dopamine overflow (two-factor ANOVA with repeated measures, effect of drug, F1,14 =1.626, NS).

---

Fig. 5. Basal extracellular dopamine concentrations in the striatum. (A) Striatal dopamine concentrations were measured by no net flux microdialysis in alert freely moving coloboma (n=8) and control mice (n=9). Values are expressed as mean±SEM. *p<0.05, Student’s t test. (B) The extraction fraction, an indirect measure of dopamine reuptake, was determined by calculating the slope of the linear regression analysis of the perfused concentration of dopamine (Cin) versus the perfused dopamine concentration minus the dialysate dopamine concentration (Cin−Cout). Values are expressed as mean±SEM. No significant difference was observed between the extraction fractions from control and coloboma mice.

Fig. 6. Amphetamine-induced dopamine efflux in striatum. (A–D) Mice (n=6–10/genotype/dose) were injected with 2 mg/kg (A), 4 mg/kg (B), 8 mg/kg (C) amphetamine or 4 mg/kg amphetamine plus 0.05 mg/kg haloperidol (D) and microdialysis samples collected in 20 min intervals. Basal values (‘B’) were calculated by averaging the dopamine concentrations from the 4 samples prior to amphetamine injection. Data are expressed as means±SEM. (E) The absolute amphetamine-induced increase in extracellular dopamine efflux in experiments A–D was determined by calculating the area under the curve (A.U.C.) after subtracting basal extracellular dopamine concentrations. Two-factor ANOVA revealed main effects of genotype (F1,53=7.58, p<0.01) and treatment (F3,53=6.85, p<0.001).
D2-like dopamine receptor-mediated responses

A reduction in dopamine efflux, which might be expected in light of the reduction in SNAP-25 expression in coloboma mice, does not explain the reduction in locomotor activity observed in response to amphetamine. Furthermore, the results presented in Figs. 1 and 2 suggest that D2 dopamine receptors mediate the amphetamine-induced reduction in locomotor activity in coloboma mice. It is well established that persistent changes in extracellular dopamine alter dopamine receptor function. We have previously demonstrated that D2-like dopamine receptor densities and affinities are normal in coloboma mice (Jones et al., 2001b). This is consistent with studies of adult rodents subjected to monoaminergic insult early in development, including neonatal 6-hydroxydopamine-lesioned rats, mice lacking dopamine due to tyrosine hydroxylase deficiency in dopaminergic neurons (DA−/− mice) and norepinephrine transporter-deficient mice, demonstrating that receptor densities and affinities are normal (Breese et al., 1985; Kim et al., 2000; Xu et al., 2000). In contrast, behavioral responses to dopaminergic challenge are enhanced in these models, suggesting that there are functional changes that result in receptor supersensitivity (for a review, see Kostrzewa, 1995). Therefore, behavioral and biochemical measures were used to examine D2-like dopamine receptor function in coloboma mice.

Mice were challenged with the D2-like dopamine receptor antagonist spiperone, which induces akinesia or catalepsy. Because catalepsy tests time spent in an unnatural position, results from control and coloboma mice are quantitatively similar, allowing the direct comparison of results from both genotypes. As shown in Fig. 7A, coloboma mice were relatively insensitive to the cataleptogenic effects of the D2 dopamine receptor antagonist spiperone and required higher doses of spiperone to induce catalepsy than control mice (p<0.05), suggesting that D2-like dopamine receptors are supersensitive in coloboma mice.

Behavioral responses to agonist challenge were assessed using quinpirole, a D2/D3 dopamine receptor agonist. Quinpirole reduced locomotor activity in coloboma and control mice (Fig. 7B). However, coloboma mice were more sensitive to the effects of quinpirole: lower doses caused a greater reduction in locomotor activity in coloboma mice than control mice (p<0.05), again reflecting supersensitivity. However, because baseline locomotor activity is much greater in coloboma mice than control mice, it is possible that the differences observed in quinpirole responses were simply a result of ceiling and floor effects rather than a true reflection of receptor sensitivity.

To investigate functional changes in signal transduction, dopamine receptor-mediated adenylate cyclase activity was assessed. No difference in basal adenylate cyclase activity was observed between control (4.7 ± 0.7 pmol/min/mg) and coloboma mice (4.1 ± 0.9 pmol/min/mg). Forskolin-stimulated adenylate cyclase activity was also comparable (control mice, 260 ± 35 pmol/min/mg; coloboma mice, 299 ± 36 pmol/min/mg). The D2/D3 dopamine receptor agonist quinpirole dose-dependently inhibited forskolin-stimulated adenylate cyclase activity with a Hill coefficient of 0.8 ± 0.1 (control mice, 260 ± 35 pmol/min/mg; coloboma mice, 299 ± 36 pmol/min/mg). The D2/D3 dopamine receptor agonist quinpirole dose-dependently inhibited forskolin-stimulated adenylate cyclase activity with a Hill coefficient of 0.8 ± 0.1 (control mice, 260 ± 35 pmol/min/mg; coloboma mice, 299 ± 36 pmol/min/mg). The D2/D3 dopamine receptor agonist quinpirole dose-dependently inhibited forskolin-stimulated adenylate cyclase activity with a Hill coefficient of 0.8 ± 0.1 (control mice, 260 ± 35 pmol/min/mg; coloboma mice, 299 ± 36 pmol/min/mg).
inhibited forskolin-stimulated adenylyl cyclase activity in both control and coloboma mice (Fig. 7C), but the inhibition was significantly greater in coloboma mice than control mice \(p<0.05\). This suggests an increase in the functional sensitivity of D2-like dopamine receptors in accord with the behavioral drug challenges.

**Discussion**

The indirect and direct dopamine agonists amphetamine and apomorphine reduced the hyperactivity exhibited by coloboma mice. This reduction in activity was not accompanied by an increase in stereotyped behavior, eliminating rate dependency as an explanation for the effect. An increase in basal extracellular dopamine was observed in coloboma mice, which may, in part, account for the hyperactivity inasmuch as increases in dopaminergic tone also occur in other models of hyperactivity (Giros et al., 1996; Zhuang et al., 2001). Despite causing a reduction in locomotor activity, amphetamine induced a dose-dependent increase in striatal dopamine efflux in coloboma mice that exceeded control mice. Thus, an abnormal reduction in neurotransmitter efflux, which might be expected in light of the reduction in SNAP-25 expression in coloboma mice, does not explain the reduction in locomotor activity induced by amphetamine. Instead, it is likely that abnormal receptor-mediated responses drive the response.

The D2-like dopamine receptor antagonists haloperidol and raclopride, but not the D1/D5 dopamine receptor antagonist SCH23390, blocked the amphetamine-induced reduction in locomotor activity in coloboma mice. In fact, haloperidol and raclopride restored amphetamine-attenuated locomotor activity to near baseline levels. Many theories and experiments in both humans and animals indirectly implicate D2 dopamine receptors in the effect of psychostimulants in ADHD (Seeman and Madras, 1998; Solanto, 1998; Ilgin et al., 2001; Zhuang et al., 2001; Viggiano et al., 2003; Lou et al., 2004). The results presented here provide the first direct evidence demonstrating that activation of D2-like, but not D1-like, dopamine receptors is necessary for the effect.

In control mice, amphetamine-induced locomotor activity was significantly increased after treatment with low doses of haloperidol, similar to previous reports (Salni et al., 1998; O’Neill and Shaw, 1999), but this effect was not observed with raclopride. Haloperidol binds to all D2-like dopamine receptor subtypes (D2, D3 and D4) whereas raclopride interacts with only D2 and D3 dopamine receptor subtypes. Because blocking D2-like dopamine receptors with haloperidol increased the stimulatory effects of amphetamine in normal mice, it follows that there is a minor inhibitory element to the amphetamine response that is mediated by D2-like dopamine receptors. That raclopride did not have similar effects suggests that D4 dopamine receptors mediate this inhibitory component of the amphetamine response. Indeed, mice lacking the D4 dopamine receptor subtype exhibit enhanced responses to amphetamine (Kruzhich et al., 2004).

D2-like dopamine receptors were functionally supersensitive in coloboma mice as demonstrated across behavioral and second messenger responses. D2-like dopamine receptors are located pre- and postsynaptically. Autoreceptors on dopaminergic neurons inhibit firing activity and neurotransmitter release. One hypothesis explaining the effects of psychostimulants suggests that the dopamine efflux caused by low doses of psychostimulants acts preferentially at dopamine autoreceptors to attenuate dopaminergic transmission (Seeman and Madras, 1998; Solanto, 1998). However, results of single unit recording performed presynaptically in the substantia nigra pars compacta and postsynaptically in either the caudate or globus pallidus from normal animals demonstrate that neither methylphenidate nor amphetamine drives autoreceptor-selective stimulation, regardless of dose (Piercey et al., 1996; Ruskin et al., 2001). Furthermore, although a large body of evidence supports a psychostimulant-induced increase in dopamine efflux in humans and animals (Imperato and Di Chiara, 1984; Kuczynski and Segal, 1989; Robinson and Camp, 1990; Volkow et al., 2001), there is little to suggest that low doses reduce overflow.

It is not likely that autoreceptors govern the amphetamine-induced reduction in locomotor activity in coloboma mice for several reasons. First, the locomotor response to an autoreceptor-selective dose of apomorphine is comparable in control and coloboma mice, suggesting that autoreceptor responses are normosensitive in these mutants (Jones et al., 2001a). Second, a robust amphetamine-induced increase in extracellular dopamine was observed in coloboma mice. Third, although the D2-like dopamine receptor antagonist haloperidol blocked the motor response to amphetamine in coloboma mice, the same dose had no obvious effect on amphetamine-induced dopamine efflux.

It is more likely that postsynaptic dopamine receptors regulate the effect of amphetamine. Stimulation of postsynaptic D2-like dopamine receptors generally reduces the excitability of medium spiny neurons in the striatum by blunting glutamatergic responses either directly at D2-like dopamine receptors expressed on medium spiny neurons or through heteroreceptors located on corticostriatal terminals that inhibit glutamate release (Brown and Arbuthnott, 1983; Cepeda et al., 1993; O’Donnell and Grace, 1994; West and Grace, 2002; Bamford et al., 2004). In contrast, most in vivo experiments and many in vitro studies suggest that D1-like dopamine receptors facilitate medium spiny neuron activity (Hu and Wang, 1988; Cepeda et al., 1993; Kiyatkin and Rebec, 1996; Gonon, 1997). The modest increase in extracellular dopamine in drug-naive coloboma mice likely overstimulates both D1- and D2-like dopamine receptors, producing hyperactivity. Further increasing extracellular dopamine via amphetamine may shift the response to favor the supersensitive D2-like dopamine receptor response resulting in a net dampening of medium spiny neuron signaling and a concomitant reduction in activity. However, this explanation is probably too simplistic because other factors may contribute to the effect, including nigrostriatal firing patterns and dysregulation of other transmitters.

Of course, these data do not exclude the possibility that other catecholamines contribute to the effect of amphetamine. Amphetamine elicits increases in synaptic norepinephrine concentrations, in addition to increasing synaptic DA. In normal animals, depletion of central norepinephrine or blockade of postsynaptic adrenergic receptors prevents the locomotor increase induced by amphetamine (Ogren et al., 1983; Archer et al., 1986; Darraju et al., 1998), suggesting a significant role for norepinephrine in the response. Furthermore, we have found that norepinephrine contributes to the expression of locomotor hyperactivity and inattention in drug-naive coloboma mice via \(\alpha_{2C}\)-adrenergic receptors (Jones and Hess, 2003; Bruno and Hess, 2006; Bruno et al., 2007), suggesting that adrenergic receptors may also contribute to psychostimulant responses. Experiments similar in design to those presented here will directly test the involvement of adrenergic receptors in the response to amphetamine.

Amphetamine, but not methylphenidate, reduces locomotor activity in coloboma mice (Hess et al., 1996). Most ADHD patients respond to both amphetamine and methylphenidate (Efron et al.,
concentrations than extremely high doses of methylphenidate in rat. First, there are important species differences in the neurochemical effects of psychostimulants. At clinically efficacious doses, amphetamine and methylphenidate induce comparable increases in extracellular dopamine in humans as assessed by positron emission tomography (PET) imaging of psychostimulant-induced emission tomography (PET) imaging of psychostimulant-induced displacement of [11C]raclopride binding (Breier et al., 1997; Volkow et al., 2001; Cardenas et al., 2004; Oswald et al., 2005; Udo de Haes et al., 2005). In contrast, even low doses of amphetamine elicit much larger increases in synaptic dopamine concentrations than extremely high doses of methylphenidate in rat (Kuczenski and Segal, 1997); we have observed similar effects in mice (unpublished observation). It is possible that the modest increase in extracellular dopamine elicited by even the highest doses of methylphenidate in rodents does not adequately stimulate the D2-like dopamine receptors given that activation of D2-like dopamine receptors requires relatively high concentrations of dopamine (Zheng et al., 1999). This hypothesis suggests that the differential response to methylphenidate and amphetamine may depend on the level of D2-like dopamine receptor sensitivity or gain. Moderate D2-like dopamine receptor supersensitivity, as observed in coloboma mice, would require high concentrations of dopamine to inhibit motor activity whereas higher receptor supersensitivity would require less dopamine, such as that provided by methylphenidate, to produce the effect.

Alternatively, the coloboma mouse may model a subset of ADHD patients. Although many consider methylphenidate and amphetamine interchangeable for the treatment of ADHD, only approximately half of affected children respond to both methylphenidate and amphetamine with equal efficacy (Arnold et al., 1978; Elia et al., 1991; Efron et al., 1997). While the majority of children benefit from methylphenidate treatment, a small subset of children respond only to amphetamine, suggesting that underlying neurochemical differences define the response to psychostimulants. Since the etiology of hyperactivity is unlikely to be ascribed to a single molecular, neuroanatomical or neurochemical substrate, no single model is likely to account for the pathogenesis and therapeutic efficacy in all ADHD patients. Because D2-like dopamine receptors are generally viewed as negative regulators of activity, D2-like dopamine receptors were implicated in the efficacy of psychostimulants in ADHD for decades. Here, we provide direct evidence in an animal model and demonstrate that it is possible to directly antagonize the effect through D2-like dopamine receptors, providing access to the mechanisms underlying the efficacy of psychostimulants in ADHD and targets for novel therapeutics.

Acknowledgments

We thank Drs. Michelle D. Jones and Irwin Lucki for consultation on the microdialysis experiments, Dr. Kristy J. Bruno for helpful discussion and Catherine Weisz for technical support. Supported by U.S. Public Health Service Grant R01 NS34845.

References


